anti-inflammatory agent

anti-inflammatory agent

[‚an·tē·in′flam·ə·tȯr·ē ‚ā·jənt]
(pharmacology)
A substance, such as cortisone, that counteracts inflammation.
References in periodicals archive ?
Celastrol, a potent anti-inflammatory agent extracted from the so-called "thunder god vine" has been seen to suppress a protein known as p23.
OMS302 is a proprietary combination of an anti-inflammatory agent and an agent that causes pupil dilation (mydriasis), each with well-known safety and pharmacologic profiles.
com) has been informed by Australia's Therapeutic Goods Administration (TGA) that its innovative anti-inflammatory agent AIMSPRO(R) has been awarded Orphan Status for the treatment of Amyotrophic Lateral Sclerosis (ALS).
An anti-inflammatory agent has been formulated by Universiti Sains Malaysia (USM), gained from a local herb to help handle inflamation and arthritic symptoms.
The new product, which contains nonsteroidal anti-inflammatory agent as a main ingredient, combats various dermatitis symptoms including insect bites, hand eczema, diaper rash and heat rash.
This therapeutic botanical extract has been used for decades internally and topically as an anti-inflammatory agent and wound healer.
Our research has shown success in reducing intimal hyperplasia when using infused ATL146e, the company's proprietary anti-inflammatory agent.
In other work pitting bacteria against disease, Lothar Steidler and his colleagues at Ghent University in Belgium genetically engineered Lacococcus lactis bacteria to make and secrete interleukin-10, an anti-inflammatory agent.
NEW YORK, April 3 /PRNewswire/ -- Pharmos Corporation (Nasdaq: PARS) today announced that it has completed the submission of the NDA for Lotemax(TM), a novel site specific ocular anti-inflammatory agent.
PROCHYMAL's unique mechanism of action may represent a new class of anti-inflammatory agent," said Jane Onken, M.
Naprelan([R]) is a non-steroidal anti-inflammatory agent that has been specially formulated using Elan's patented IPDAS[TM] (Intestinal Protective Drug Absorption System) technology.
is presenting clinical and preclinical data from studies of the company's drug candidate Traficet-EN[R] (CCX282-B) a first-in-class, orally active, anti-inflammatory agent that targets the chemokine receptor known as CCR9, at the 2006 Crohn's and Colitis Foundation of America's (CCFA) National Research and Clinical Conference/Fifth Annual Advances in the Inflammatory Bowel Diseases meeting being held December 1-3, 2006 in Miami, FL.